ACADIA Pharmaceuticals Director Sells $1,519,552 in Stock (ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD) Director Lester Ph Kaplan sold 66,356 shares of ACADIA Pharmaceuticals stock on the open market in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $22.90, for a total transaction of $1,519,552.40. Following the transaction, the director now directly owns 8,500 shares of the company’s stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
ACAD has been the subject of a number of recent research reports. Analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from $20.00 to $23.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note to investors on Wednesday, August 7th. They now have a $26.00 price target on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from $15.00 to $24.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock.
One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.43.
ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 1.81% during mid-day trading on Friday, hitting $23.12. The stock had a trading volume of 2,247,053 shares. ACADIA Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $23.49. The stock has a 50-day moving average of $20.6 and a 200-day moving average of $15.00. The company’s market cap is $2.053 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, August 6th. The company reported ($0.11) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.09) by $0.02. The company had revenue of $451.00 million for the quarter, compared to the consensus estimate of $0.45 million.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.